Effect of angiotensin-converting enzyme inhibitors versus that of angiotensin receptor blockers on survival in patients undergoing hemodialysis: a nationwide observational cohort study

References

• ESRD Registry Committee: Korean Society of Nephrology. Current renal replacement therapy in Korea, 2021. ­[assessed 14 June 2023]. Available from: https://ksn.or.kr/bbs/index.php?code=report
   Google Scholar
• US Renal Data System. USRDS 2020 annual data report: atlas of chronic kidney disease in the United States. Bethesda (MD): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2020.
   Google Scholar
• Choi H, Kim M, Kim H, et al. Excess mortality among patients on dialysis: comparison with the general population in Korea. Kidney Res Clin Pract. 2014;33(2):1–10. doi: 10.1016/j.krcp.2014.04.001.
   PubMedGoogle Scholar
• Yusuf S, Pitt B, Davis CE, et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293–302. doi: 10.1056/NEJM199108013250501.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Braunwald E, Moyé LA, et al. The save investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med. 1992;327(10):669–677. doi: 10.1056/NEJM199209033271001.
   PubMed Web of Science ®Google Scholar
• The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821–828.
   PubMed Web of Science ®Google Scholar
• Allikmets K, Parik T, Viigimaa M. The renin-angiotensin system in essential hypertension: associations with cardiovascular risk. Blood Press. 1999;8(2):70–78. doi: 10.1080/080370599438239.
   PubMed Web of Science ®Google Scholar
• Kidney Disease: improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;99(3S):S1–S87. doi: 10.1016/j.kint.2020.11.003.
   PubMedGoogle Scholar
• Georgianos PI, Tziatzios G, Roumeliotis S, et al. Effect of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on cardiovascular outcomes in dialysis patients: a systematic review and meta-analysis. Nephrol Dial Transplant. 2023;38(1):203–211. doi: 10.1093/ndt/gfac253.
   PubMed Web of Science ®Google Scholar
• Kang SH, Kim BY, Son EJ, et al. Comparison of patient survival according to Erythropoiesis-Stimulating agent type of treatment in maintenance hemodialysis patients. J Clin Med. 2023;12(2):625. doi: 10.3390/jcm12020625.
   PubMed Web of Science ®Google Scholar
• Health Insurance Review & Assessment Service. 6th Hemodialysis quality assessment program. [assessed 14 June 2023]. Available from: https://www.hira.or.kr/bbsDummy.do?pgmid=HIRAA020002000100&brdScnBltNo=4&brdBltNo=6619#none
   Google Scholar
• Daugirdas JT. Second generation logarithmic estimates of single-Pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol. 1993;4(5):1205–1213. doi: 10.1681/ASN.V451205.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi: 10.1016/0021-9681(87)90171-8.
   PubMedGoogle Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–1139. doi: 10.1097/01.mlr.0000182534.19832.83.
   PubMed Web of Science ®Google Scholar
• Shireman TI, Mahnken JD, Phadnis MA, et al. Comparative effectiveness of renin-angiotensin system antagonists in maintenance dialysis patients. Kidney Blood Press Res. 2016;41(6):873–885. doi: 10.1159/000452590.
   PubMed Web of Science ®Google Scholar
• Kido R, Akizawa T, Fukagawa M, et al. Interactive effectiveness of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers or their combination on survival of hemodialysis patients. Am J Nephrol. 2017;46(6):439–447. doi: 10.1159/000482013.
   PubMed Web of Science ®Google Scholar
• Chan KE, Ikizler TA, Gamboa JL, et al. Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients. Kidney Int. 2011;80(9):978–985. doi: 10.1038/ki.2011.228.
   PubMed Web of Science ®Google Scholar
• Messerli FH, Bangalore S, Ram VS, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;359(4):426–427; author reply 427.
   PubMedGoogle Scholar
• Xie X, Liu Y, Perkovic V, et al. Renin-Angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis. 2016;67(5):728–741. doi: 10.1053/j.ajkd.2015.10.011.
   PubMed Web of Science ®Google Scholar
• Shen JI, Saxena AB, Montez-Rath ME, et al. Comparative effectiveness of angiotensin receptor blockers vs. angiotensin-converting enzyme inhibitors on cardiovascular outcomes in patients initiating peritoneal dialysis. J Nephrol. 2017;30(2):281–288. doi: 10.1007/s40620-016-0340-3.
   PubMed Web of Science ®Google Scholar
• van Vark LC, Bertrand M, Akkerhuis KM, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J. 2012;33(16):2088–2097. doi: 10.1093/eurheartj/ehs075.
   PubMed Web of Science ®Google Scholar
• Suzuki H. Therapeutic efficacy of renin-angiotensin blockade in patients receiving dialysis. Ther Adv Cardiovasc Dis. 2009;3(5):397–405. doi: 10.1177/1753944709338339.
   PubMedGoogle Scholar
• Wenzel UO, Krebs C, Benndorf R. The angiotensin II type 2 receptor in renal disease. J Renin Angiotensin Aldosterone Syst. 2010;11(1):37–41. doi: 10.1177/1470320309347787.
   PubMed Web of Science ®Google Scholar
• Kovarik JJ, Antlanger M, Domenig O, et al. Molecular regulation of the renin-angiotensin system in haemodialysis patients. Nephrol Dial Transplant. 2015;30(1):115–123. doi: 10.1093/ndt/gfu265.
   PubMed Web of Science ®Google Scholar
• Gamboa JL, Pretorius M, Todd-Tzanetos DR, et al. Comparative effects of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on inflammation during hemodialysis. J Am Soc Nephrol. 2012;23(2):334–342. doi: 10.1681/ASN.2011030287.
   PubMed Web of Science ®Google Scholar
• Cice G, Di Benedetto A, D’Isa S, et al. Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis ­patients with chronic heart failure a double-blind, placebo-controlled trial. J Am Coll Cardiol. 2010;56(21):1701–1708. doi: 10.1016/j.jacc.2010.03.105.
   PubMed Web of Science ®Google Scholar
• Denker MG, Cohen DL. Antihypertensive medications in end-stage renal disease. Semin Dial. 2015;28(4):330–336. doi: 10.1111/sdi.12369.
   PubMed Web of Science ®Google Scholar
• Iseki K, Arima H, Kohagura K, et al. Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial. Nephrol Dial Transplant. 2013;28(6):1579–1589. doi: 10.1093/ndt/gfs590.
   PubMed Web of Science ®Google Scholar
• Zannad F, Kessler M, Lehert P, et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int. 2006;70(7):1318–1324. doi: 10.1038/sj.ki.5001657.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Sinha AD, Pappas MK, et al. Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. Nephrol Dial Transplant. 2014;29(3):672–681. doi: 10.1093/ndt/gft515.
   PubMed Web of Science ®Google Scholar
• Weir MA, Fleet JL, Dixon SN, et al. Angiotensin converting enzyme inhibitor dialyzability and outcomes in ­older patients receiving hemodialysis. Blood Purif. 2015;40(3):232–242. doi: 10.1159/000438821.
   PubMed Web of Science ®Google Scholar
• Luño J, Varas J, Ramos R, et al. The combination of beta blockers and renin-angiotensin system blockers ­improves survival in incident hemodialysis patients: a propensity-matched study. Kidney Int Rep. 2017;2(4):665–675. doi: 10.1016/j.ekir.2017.03.001.
   PubMed Web of Science ®Google Scholar